JP Morgan Chase’s KALA BIO KALA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-600
| Closed | -$5.13K | – | 7918 |
|
|
2026
Q1 | $5.13K | Buy |
600
+599
| +59,900% | +$12.7K | ﹤0.01% | 6883 |
|
|
2025
Q4 | $29 | Hold |
1
| – | – | ﹤0.01% | 7279 |
|
|
2025
Q3 | $78 | Sell |
1
-4
| -80% | -$1.98K | ﹤0.01% | 7191 |
|
|
2025
Q2 | $1.13K | Buy |
5
+4
| +400% | +$780 | ﹤0.01% | 6610 |
|
|
2025
Q1 | $344 | Hold |
1
| – | – | ﹤0.01% | 6736 |
|
|
2024
Q4 | $416 | Hold |
1
| – | – | ﹤0.01% | 6822 |
|
|
2024
Q3 | $228 | Hold |
1
| – | – | ﹤0.01% | 6893 |
|
|
2024
Q2 | $248 | Hold |
1
| – | – | ﹤0.01% | 6761 |
|
|
2024
Q1 | $274 | Hold |
1
| – | – | ﹤0.01% | 6776 |
|
|
2023
Q4 | $217 | Hold |
1
| – | – | ﹤0.01% | 7039 |
|
|
2023
Q3 | $276 | Hold |
1
| – | – | ﹤0.01% | 6801 |
|
|
2023
Q2 | $569 | Hold |
1
| – | – | ﹤0.01% | 6531 |
|
|
2023
Q1 | $0 | Sell |
1
-10
| -91% | -$8.72K | ﹤0.01% | 6975 |
|
|
2022
Q4 | $21K | Buy |
11
+10
| +1,000% | +$3.96K | ﹤0.01% | 5867 |
|
|
2022
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 6665 |
|
|
2022
Q2 | $0 | Sell |
1
-21
| -95% | -$32.9K | ﹤0.01% | 6683 |
|
|
2022
Q1 | $77K | Sell |
22
-2
| -8% | -$5.24K | ﹤0.01% | 5620 |
|
|
2021
Q4 | $73K | Sell |
24
-6
| -20% | -$27.8K | ﹤0.01% | 5803 |
|
|
2021
Q3 | $195K | Sell |
30
-3
| -9% | -$25.9K | ﹤0.01% | 5245 |
|
|
2021
Q2 | $433K | Buy |
33
+1
| +3% | +$15.7K | ﹤0.01% | 4781 |
|
|
2021
Q1 | $533K | Sell |
32
-1
| -3% | -$19.5K | ﹤0.01% | 4637 |
|
|
2020
Q4 | $567K | Sell |
33
-35
| -51% | -$659K | ﹤0.01% | 4294 |
|
|
2020
Q3 | $1.35M | Buy |
68
+27
| +66% | +$621K | ﹤0.01% | 3472 |
|
|
2020
Q2 | $1.09M | Buy |
41
+5
| +14% | +$142K | ﹤0.01% | 3461 |
|
|
2020
Q1 | $792K | Sell |
36
-52
| -59% | -$831K | ﹤0.01% | 3559 |
|
|
2019
Q4 | $811K | Sell |
88
-17
| -16% | -$164K | ﹤0.01% | 3986 |
|
|
2019
Q3 | $997K | Buy |
105
+2
| +2% | +$24.3K | ﹤0.01% | 3839 |
|
|
2019
Q2 | $1.51M | Sell |
103
-3
| -3% | -$49.7K | ﹤0.01% | 3564 |
|
|
2019
Q1 | $2.19M | Buy |
106
+3
| +3% | +$53.3K | ﹤0.01% | 3264 |
|
|
2018
Q4 | $1.25M | Buy |
103
+39
| +61% | +$676K | ﹤0.01% | 3603 |
|
|
2018
Q3 | $1.58M | Buy |
64
+17
| +36% | +$518K | ﹤0.01% | 3625 |
|
|
2018
Q2 | $1.6M | Sell |
47
-34
| -42% | -$1.3M | ﹤0.01% | 3554 |
|
|
2018
Q1 | $3.18M | Sell |
81
-9
| -10% | -$342K | ﹤0.01% | 2940 |
|
|
2017
Q4 | $4.15M | Buy |
90
+20
| +29% | +$936K | ﹤0.01% | 2827 |
|
|
2017
Q3 | $4.04M | Buy |
+70
| New | +$3.84M | ﹤0.01% | 2716 |
|
Other funds holding KALA
TRCT
JP Morgan Chase's KALA Position: Q2 2026 in Review
JP Morgan Chase sold out of KALA BIO (KALA) in Q2 2026, closing a stake of 600 shares — an estimated $5.13K sold.
JP Morgan Chase first reported a position in KALA in Q3 2017 and held it in 35 quarters. The position peaked at $4.15M in Q4 2017. 14 funds tracked by Wall St. Rank hold KALA as of Q2 2026.
- JP Morgan Chase reported no remaining KALA BIO position as of Q2 2026 after selling out during the quarter.
- JP Morgan Chase sold 600 KALA BIO shares in Q2 2026, an estimated $5.13K.
- JP Morgan Chase first reported a position in KALA BIO in Q3 2017 and held it in 35 quarters.
- JP Morgan Chase's KALA BIO position peaked at $4.15M in Q4 2017.
- 14 funds tracked by Wall St. Rank held KALA BIO as of Q2 2026.
Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.